Allergan on the Street: Analyst Recommendations This December


Dec. 11 2017, Updated 10:30 a.m. ET

Wall Street’s estimates

Wall Street analysts estimate that Allergan’s (AGN) top line will rise 10.5% YoY (year-over-year) to $4.27 billion in 4Q17, compared with $3.86 billion in 4Q16.

Analysts also estimate that Allergan’s annual revenues will rise ~9% YoY to ~$15.9 billion in 2017, compared with ~$14.6 billion in 2016. Its EPS (earnings per share) expectation is $16.24 for 2017.

Article continues below advertisement

Analysts’ ratings

Allergan’s stock price has fallen ~14.0% the past 12 months and ~21.7% so far in 2017, or YTD (year-to-date). The analysts’ estimates show that the stock has a potential to return ~39.9% over the next 12 months.

The analysts’ recommendations show a 12-month target price of $229.90 per share, compared with its last price of $164.28 per share on December 5, 2017.

Analyst recommendations

As of December 6, 2017, of the 24 analysts tracking Allergan stock, 17 recommend a “buy,” while seven recommend a “hold.” None recommends a “sell.” The consensus rating for Allergan now stands at 2.0, which represents a “strong buy” for momentum and long-term investors.

Remember, changes in analysts’ recommendations are based on changes in the stock’s price, the performance of the company, and positive developments.

Notably, the iShares Core S&P 500 ETF (IVV) has 14.0% of its total assets in Healthcare companies. IVV has 0.2% in Allergan (AGN), 1.0% in Pfizer (PFE), 0.7% in Merck (MRK), and 0.6% in Amgen (AMGN).


More From Market Realist

    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.